Which funds bought or sold EW in Q3 2026?
Edwards Lifesciences Corp. 8 funds bought, 2 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$16M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Arrowstreet+$390M
- Millennium+$194M
- Balyasny+$76M
- Jennison+$50M
- Adage+$47M
- Baillie Gifford+$46M
- Schonfeld+$28M
- PRIMECAP+$15M
- AllianceBernstein−$95M
- Brown Advisory−$79M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (8)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Arrowstreet Quant & multi-strategy | Added+79.6% | +$390M | $880M |
| Millennium Quant & multi-strategy | Added+62.8% | +$194M | $504M |
| Balyasny Quant & multi-strategy | Added+192.8% | +$76M | $115M |
| Jennison Growth / crossover | Added+244% | +$50M | $71M |
| Adage Hedge fund | Added+75.7% | +$47M | $109M |
| Baillie Gifford Growth / crossover | Added+44% | +$46M | $150M |
| Schonfeld Quant & multi-strategy | Added+173.8% | +$28M | $45M |
| PRIMECAP Growth / crossover | Added+5.2% | +$15M | $309M |
Sold (2)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| AllianceBernstein Asset manager | Trimmed-12.7% | −$95M | $653M |
| Brown Advisory Asset manager | Trimmed-12.3% | −$79M | $557M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.